Literature DB >> 8678062

Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A.

M J Flanigan1, L Pillsbury, G Sadewasser, V S Lim.   

Abstract

Regional citrate anticoagulation should be a simple process of substituting hypertonic (1.6 mol/L) citrate for heparin and adjusting the infusion to obtain an arterial activated clotting time of 150 to 200 seconds. Serious, documented complications of citrate anticoagulation involve citrate intoxication during isolated ultrafiltration; hyperaluminemia, hyperammonemia, and hypernatremia during sorbent dialysis; and profound alkalosis, paresthesias, arrhythmia, and cardiac arrest during bicarbonate dialysis. We suspected that some of these complications could be avoided by using anticoagulant citrate dextrose-A (ACD) rather than hypertonic tri-sodium citrate (TSC) as the anticoagulant. In a cross-over study with random assignment order eight adults underwent mid-week dialyses with ACD (0.113 mol/L citrate) and TSC (1.6 mol/L citrate) regional citrate anticoagulation. Predialysis to postdialysis changes in Na (mEq/L), Ca (mg/dL), ionized Ca (mg/dL), pH, and HCO3 (mEq/L) are listed below. [Table in journal] Using continuous blood flow and avoiding isolated ultrafiltration and sorbent dialysis should prevent the delivery system complications of regional citrate anticoagulation. During this evaluation isotonic and hypertonic citrate resulted in similar serum sodium changes, and standard dialysate effectively reversed the citrate/calcium interaction of both hypertonic and isotonic citrate infusions to restore homeostasis without a separate calcium infusion. The combination of TSC and bicarbonate dialysate does produce a profound metabolic alkalosis, which is lessened by using ACD. In general, regional citrate anticoagulation is simplified by using standard dialysate with a hypertonic rather than an isotonic citrate infusion, and dangerous complications are further evaded by adjusting the dialysate bicarbonate to 25 to 30 mmol/L or substituting a mixture of citric acid and TSC (ACD) for TSC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8678062     DOI: 10.1016/s0272-6386(96)90162-6

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  7 in total

Review 1.  Anticoagulation techniques in apheresis: from heparin to citrate and beyond.

Authors:  Grace Lee; Gowthami M Arepally
Journal:  J Clin Apher       Date:  2012-04-24       Impact factor: 2.821

2.  Continuous renal replacement treatment and the 'bleeding patient'.

Authors:  Hugh Davies; Gavin Leslie; David Morgan
Journal:  BMJ Case Rep       Date:  2011-01-11

3.  Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit.

Authors:  Andrew Davenport; Ashita Tolwani
Journal:  NDT Plus       Date:  2009-09-25

4.  A simplified protocol for individualized regional citrate anticoagulation for hemodialysis: A single-center, randomized clinical study.

Authors:  Laimin Luo; Meirong Fan; Qinkai Chen; Jing Cheng
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

5.  A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients.

Authors:  Anne Kit-Hung Leung; Hoi-Ping Shum; King-Chung Chan; Stanley Choi-Hung Chan; Kang Yiu Lai; Wing-Wa Yan
Journal:  Crit Care Res Pract       Date:  2013-01-28

6.  Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients.

Authors:  Vincenzo Panichi; Enrico Fiaccadori; Alberto Rosati; Roberto Fanelli; Giada Bernabini; Alessia Scatena; Francesco Pizzarelli
Journal:  ScientificWorldJournal       Date:  2013-12-03

7.  Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory?

Authors:  Chloé Medrano; Olivier Cointault; Laurence Lavayssiere; Marie-Béatrice Nogier; Eloïse Colliou; Nicolas Setbon; Nassim Kamar; Stanislas Faguer
Journal:  Clin Kidney J       Date:  2021-04-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.